3 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
| 1 | 35287683 | Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer. | 2022 Mar 14 | 1 |
| 2 | 33992097 | ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition. | 2021 May 15 | 1 |
| 3 | 30111817 | Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. | 2019 Jan | 1 |